WIRE)--"Exavir Therapeutics, a company dedicated to transforming the lives of patients with chronic viral infections and CNS disorders with ultra-long-acting therapeutics, today announced that the company has received a $3M award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institute of Health (NIH), to support the development of XVIR-110."

Murray was probably working on this for exavir at the time Dr Jay contacted him and therefore stalled cydy as the competition.